Epidermal fatty acid-binding protein

A novel marker in the diagnosis of dry eye disease in sjögren syndrome

Megumi Shinzawa, Murat Dogru, Seika Den, Takehiro Ichijima, Kazunari Higa, Takashi Kojima, Noriyuki Seta, Takeshi Nomura, Kazuo Tsubota, Jun Shimazaki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Sjögren syndrome (SS) is a chronic inflammatory autoimmune disease of the lacrimal and salivary glands. This study compared the concentrations of epidermal fatty-acid binding protein (E-FABP) in the saliva, serum, and tears of SS patients with dry eye and dry mouth, with those of healthy adults to investigate the usefulness of E-FABP as a diagnostic marker for SS. Design: Prospective, observational case series. Participants: The subjects were 11 new patients with untreated Sjogren syndrome and 12 healthy control individuals. Methods: The diagnosis of SS was in accordance with the Ministry of Health, Labour and Welfare (Japan) Diagnostic Criteria (1999). Saliva, serum, and tear specimens were collected during internal medicine, dental, and ophthalmological examinations. The ophthalmological tests included the Dry Eye-related Quality of life Score (DEQS), tear break-up time (BUT), vital staining with fluorescein (FS) and lissamine green (LG), and the Schirmer test-1. The E-FABP concentration in the tears, saliva, and serum was measured by enzyme-linked immunosorbent assay (ELISA). Main outcome measure: The E-FABP concentrations were compared between patients and controls. Results: There were significant differences between the patient and healthy control groups in all ophthalmological test results. There were no significant differences between the groups in the E-FABP concentrations in the saliva (p = 0.1513) or the serum (p = 0.4799), but the E-FABP concentration in the tears significantly differed between groups. The E-FABP concentration in tears tended to be significantly lower in patients with SS (mean, 323.5 ± 325.6 pg/mL) than healthy control subjects (mean, 4076 pg/mL; p = 0.0136). The E-FABP concentration in tears significantly correlated with the results of dry eye parameters. Conclusion: The E-FABP concentration in tears appears to be related to ocular surface epithelial damage and tear stability and may be a promising novel biomarker in the diagnosis of SS.

Original languageEnglish
Article number3463
JournalInternational Journal of Molecular Sciences
Volume19
Issue number11
DOIs
Publication statusPublished - 2018 Nov 4

Fingerprint

eye diseases
Fatty Acid-Binding Proteins
Eye Diseases
Staphylococcal Protein A
fatty acids
Tears
Fatty acids
markers
proteins
saliva
Saliva
serums
Serum
salivary glands
Carrier Proteins
Lacrimal Apparatus
Immunosorbents
glands
labor
mouth

Keywords

  • Dry eye
  • Epidermal fatty-acid binding protein (E-FABP)
  • Sjögren’s syndrome
  • Tears

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Epidermal fatty acid-binding protein : A novel marker in the diagnosis of dry eye disease in sjögren syndrome. / Shinzawa, Megumi; Dogru, Murat; Den, Seika; Ichijima, Takehiro; Higa, Kazunari; Kojima, Takashi; Seta, Noriyuki; Nomura, Takeshi; Tsubota, Kazuo; Shimazaki, Jun.

In: International Journal of Molecular Sciences, Vol. 19, No. 11, 3463, 04.11.2018.

Research output: Contribution to journalArticle

Shinzawa, Megumi ; Dogru, Murat ; Den, Seika ; Ichijima, Takehiro ; Higa, Kazunari ; Kojima, Takashi ; Seta, Noriyuki ; Nomura, Takeshi ; Tsubota, Kazuo ; Shimazaki, Jun. / Epidermal fatty acid-binding protein : A novel marker in the diagnosis of dry eye disease in sjögren syndrome. In: International Journal of Molecular Sciences. 2018 ; Vol. 19, No. 11.
@article{5568747c443b4faba42aca681ed5fad3,
title = "Epidermal fatty acid-binding protein: A novel marker in the diagnosis of dry eye disease in sj{\"o}gren syndrome",
abstract = "Purpose: Sj{\"o}gren syndrome (SS) is a chronic inflammatory autoimmune disease of the lacrimal and salivary glands. This study compared the concentrations of epidermal fatty-acid binding protein (E-FABP) in the saliva, serum, and tears of SS patients with dry eye and dry mouth, with those of healthy adults to investigate the usefulness of E-FABP as a diagnostic marker for SS. Design: Prospective, observational case series. Participants: The subjects were 11 new patients with untreated Sjogren syndrome and 12 healthy control individuals. Methods: The diagnosis of SS was in accordance with the Ministry of Health, Labour and Welfare (Japan) Diagnostic Criteria (1999). Saliva, serum, and tear specimens were collected during internal medicine, dental, and ophthalmological examinations. The ophthalmological tests included the Dry Eye-related Quality of life Score (DEQS), tear break-up time (BUT), vital staining with fluorescein (FS) and lissamine green (LG), and the Schirmer test-1. The E-FABP concentration in the tears, saliva, and serum was measured by enzyme-linked immunosorbent assay (ELISA). Main outcome measure: The E-FABP concentrations were compared between patients and controls. Results: There were significant differences between the patient and healthy control groups in all ophthalmological test results. There were no significant differences between the groups in the E-FABP concentrations in the saliva (p = 0.1513) or the serum (p = 0.4799), but the E-FABP concentration in the tears significantly differed between groups. The E-FABP concentration in tears tended to be significantly lower in patients with SS (mean, 323.5 ± 325.6 pg/mL) than healthy control subjects (mean, 4076 pg/mL; p = 0.0136). The E-FABP concentration in tears significantly correlated with the results of dry eye parameters. Conclusion: The E-FABP concentration in tears appears to be related to ocular surface epithelial damage and tear stability and may be a promising novel biomarker in the diagnosis of SS.",
keywords = "Dry eye, Epidermal fatty-acid binding protein (E-FABP), Sj{\"o}gren’s syndrome, Tears",
author = "Megumi Shinzawa and Murat Dogru and Seika Den and Takehiro Ichijima and Kazunari Higa and Takashi Kojima and Noriyuki Seta and Takeshi Nomura and Kazuo Tsubota and Jun Shimazaki",
year = "2018",
month = "11",
day = "4",
doi = "10.3390/ijms19113463",
language = "English",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Epidermal fatty acid-binding protein

T2 - A novel marker in the diagnosis of dry eye disease in sjögren syndrome

AU - Shinzawa, Megumi

AU - Dogru, Murat

AU - Den, Seika

AU - Ichijima, Takehiro

AU - Higa, Kazunari

AU - Kojima, Takashi

AU - Seta, Noriyuki

AU - Nomura, Takeshi

AU - Tsubota, Kazuo

AU - Shimazaki, Jun

PY - 2018/11/4

Y1 - 2018/11/4

N2 - Purpose: Sjögren syndrome (SS) is a chronic inflammatory autoimmune disease of the lacrimal and salivary glands. This study compared the concentrations of epidermal fatty-acid binding protein (E-FABP) in the saliva, serum, and tears of SS patients with dry eye and dry mouth, with those of healthy adults to investigate the usefulness of E-FABP as a diagnostic marker for SS. Design: Prospective, observational case series. Participants: The subjects were 11 new patients with untreated Sjogren syndrome and 12 healthy control individuals. Methods: The diagnosis of SS was in accordance with the Ministry of Health, Labour and Welfare (Japan) Diagnostic Criteria (1999). Saliva, serum, and tear specimens were collected during internal medicine, dental, and ophthalmological examinations. The ophthalmological tests included the Dry Eye-related Quality of life Score (DEQS), tear break-up time (BUT), vital staining with fluorescein (FS) and lissamine green (LG), and the Schirmer test-1. The E-FABP concentration in the tears, saliva, and serum was measured by enzyme-linked immunosorbent assay (ELISA). Main outcome measure: The E-FABP concentrations were compared between patients and controls. Results: There were significant differences between the patient and healthy control groups in all ophthalmological test results. There were no significant differences between the groups in the E-FABP concentrations in the saliva (p = 0.1513) or the serum (p = 0.4799), but the E-FABP concentration in the tears significantly differed between groups. The E-FABP concentration in tears tended to be significantly lower in patients with SS (mean, 323.5 ± 325.6 pg/mL) than healthy control subjects (mean, 4076 pg/mL; p = 0.0136). The E-FABP concentration in tears significantly correlated with the results of dry eye parameters. Conclusion: The E-FABP concentration in tears appears to be related to ocular surface epithelial damage and tear stability and may be a promising novel biomarker in the diagnosis of SS.

AB - Purpose: Sjögren syndrome (SS) is a chronic inflammatory autoimmune disease of the lacrimal and salivary glands. This study compared the concentrations of epidermal fatty-acid binding protein (E-FABP) in the saliva, serum, and tears of SS patients with dry eye and dry mouth, with those of healthy adults to investigate the usefulness of E-FABP as a diagnostic marker for SS. Design: Prospective, observational case series. Participants: The subjects were 11 new patients with untreated Sjogren syndrome and 12 healthy control individuals. Methods: The diagnosis of SS was in accordance with the Ministry of Health, Labour and Welfare (Japan) Diagnostic Criteria (1999). Saliva, serum, and tear specimens were collected during internal medicine, dental, and ophthalmological examinations. The ophthalmological tests included the Dry Eye-related Quality of life Score (DEQS), tear break-up time (BUT), vital staining with fluorescein (FS) and lissamine green (LG), and the Schirmer test-1. The E-FABP concentration in the tears, saliva, and serum was measured by enzyme-linked immunosorbent assay (ELISA). Main outcome measure: The E-FABP concentrations were compared between patients and controls. Results: There were significant differences between the patient and healthy control groups in all ophthalmological test results. There were no significant differences between the groups in the E-FABP concentrations in the saliva (p = 0.1513) or the serum (p = 0.4799), but the E-FABP concentration in the tears significantly differed between groups. The E-FABP concentration in tears tended to be significantly lower in patients with SS (mean, 323.5 ± 325.6 pg/mL) than healthy control subjects (mean, 4076 pg/mL; p = 0.0136). The E-FABP concentration in tears significantly correlated with the results of dry eye parameters. Conclusion: The E-FABP concentration in tears appears to be related to ocular surface epithelial damage and tear stability and may be a promising novel biomarker in the diagnosis of SS.

KW - Dry eye

KW - Epidermal fatty-acid binding protein (E-FABP)

KW - Sjögren’s syndrome

KW - Tears

UR - http://www.scopus.com/inward/record.url?scp=85056085909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056085909&partnerID=8YFLogxK

U2 - 10.3390/ijms19113463

DO - 10.3390/ijms19113463

M3 - Article

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 11

M1 - 3463

ER -